English

RLS GLOBAL AB (PUBL) INTERIM REPORT, Q2, 2022

Report this content

APRIL 1st – JUNE 30th (Previous year in brackets)

  • Net sales amounted to TSEK 397 (TSEK 244).
  • Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5).
  • Earning per share before dilution at SEK -0,09 (SEK 0,13).
  • Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280).
  • Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
  • Equity ratio was 43 % (87 %).
     

JANUARY 1st – JUNE 30th (Previous year in brackets)

  • Net sales amounted to TSEK 705 (TSEK 302).
  • Earnings before interest and taxes (EBIT) amounted to MSEK -11,1 (MSEK 2,2).
  • Earning per share before dilution at SEK -0,16 (SEK 0,03).
  • Cash flow from operating activities amounted to MSEK -12,7 (MSEK -12,1).
  • Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
  • Equity ratio was 43 % (87 %).
     

SUMMARY OF EVENTS DURING SECOND QUARTER

  • AGM was held on May 19.
  • RLS signs distribution agreement for the Middle East with the aim of commercializing ChloraSolv.
  • RLS introduces ChloraSolv for the animal segment in Scandinavia. Distribution agreements are signed with Swevet for Denmark, Norway and Sweden.
  • ChloraSolv is approved for leg ulcers in Kuwait.
     

SUMMARY OF EVENTS AFTER SECOND QUARTER

  • The Journal of Wound Care publishes case studies regarding ChloraSolv from three British clinics.
  • Björn Larsson takes over as CEO of RLS Global as of October 1, 2022.
     

The Interim Report Q2, 2022, is enclosed and is also available here.

PUBLICATION
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on August 26th 2022.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.

FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51

Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS intends to work with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global

Subscribe

Documents & Links